Biotech Holdings Ltd.

Biotech Holdings Ltd.

Biotech Holdings Ltd. is a Vancouver-based integrated pharmaceutical company engaged in research, development, manufacture and marketing of pharmaceutical, personal care and health products. Biotech's primary focus is the manufacture and international marketing of Diab II, a new prescription drug, taken in tablet form, for the treatment of Type II Diabetes. Diab II acts to increase the body's ability to utilize its insulin, resulting in improved metabolism and an enhanced sense of well-being for the patient. This increased insulin sensitivity results in decreased blood sugar levels in those suffering from Type II Diabetes.

All three stages of clinical trials on Diab II have been completed in China. The clinical trial process involved three hospitals, 60 doctors and 1,500 patients. As a result of the positive outcome of these clinical trials the Ministry of Public Health in China has issued a New Drug Approval Number for Diab II, enabling the drug to be marketed and sold throughout China.

Supplementary clinical trials have also been undertaken in the Caribbean, where in addition to seeking approval for marketing, this trial is also conducting tests to confirm supplemental uses for Diab II.

Biotech's Personal Care Products Division manufactures a number of non-prescription products, including sunscreens, creams, lotions and bath products, which are sold primarily to national-chain retailers in the United States and Canada. Biotech plans to continue expanding the revenues and product range of this Division so that it can continue to support the expansion of Diab II.

Biotech is focusing its marketing of Diab II on global markets. In addition to marketing in China, the company has expanded to the Latin American market and preliminary agreements have been signed in Peru. Similar agreements are expected in Argentina, Uruguay and Brazil. Marketing and distribution operations will eventually be expanded to include Africa, India, Pakistan and the middle East as well as Canada, the US and Europe. Biotech has signed an agreement with a major American pharmaceutical firm to begin testing of Diab II for the purpose of possible licensing of the drug;

Biotech has signed an agreement with a major European-based pharmaceutical company for testing of Diab II for the purpose of co-marketing Diab II in China; Biotech has begun the process of registration of Diab II in several South American countries and expects to begin marketing Diab II in some of these countries during the current fiscal year;

Biotech Holdings' shares trade on the Alberta Stock Exchange (symbol: BIO) and on the Over the Counter Bulletin Board in the United States (OTC BB symbol: BlOHF).

Company Details

Year Established: 1989

Company Information

Robert Rieveley
Title: President
Fax: (604) 736-3806

Products

Vitamin/Health Supplements

Services